Join Clinical Trials in Wisconsin for Allergies

All Categories Medical Conditions » Allergies » Wisconsin

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012
Improving Nutrient Intake and Growth in Children With Multiple Food Allergies

Condition: Food Allergy
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin
Recruiting - verified April 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2012
A Study of ARRY-502 in Patients With Persistent Asthma

Condition: Asthma
Interventions: Drug: ARRY-502, CRTh2 antagonist; oral; Drug: Placebo; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified May 2012
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease

Conditions: Asthma; Chronic Obstructive Pulmonary Disease; Obstructive Sleep Apnea
Intervention: Drug: Inhaled Fluticasone Propionate
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified March 2012
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Matching Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2012
Innate Immunity and the Allergic Response

Condition: Nasal Allergies
Intervention: Other: allergen challenge
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Merck
Recruiting - verified April 2012
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Bronchial Thermoplasty in Severe Persistent Asthma

Condition: Severe Asthma
Intervention: Device: Alair System
Sponsors: Asthmatx, Inc.; Asthmatx, Inc.; Boston Scientific Corporation
Recruiting - verified March 2012
Efficacy, Safety, and Tolerability of SAR231893(REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Condition: Asthma
Interventions: Biological: SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsors: Cephalon; Cephalon
Recruiting - verified April 2012
Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma

Condition: Asthma
Interventions: Drug: Vitamin D3; Drug: Ciclesonide
Sponsors: Milton S. Hershey Medical Center; Milton S. Hershey Medical Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012
Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis

Conditions: Atopic Dermatitis; Vitamin D Deficiency; Asthma
Intervention:
Sponsors: Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital and Health System Foundation, Wisconsin
Recruiting - verified July 2011
A Non-drug Study Profiling Asthma

Conditions: Asthma; Health
Intervention: Other: All patients
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

Condition: Asthma
Interventions: Drug: budesonide; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Condition: Asthma
Interventions: Drug: Imatinib mesylate; Drug: Placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Harvard Clinical Research Institute; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012
Functional Activity of Airway Eosinophils in Allergic Disease

Condition: Asthma
Intervention: Biological: Segmental Allergen Challenge
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Institutes of Health (NIH)
Recruiting - verified September 2011
Asthma and Obstructive Sleep Apnea (OSA)

Conditions: Asthma; Obstructive Sleep Apnea
Interventions: Other: FDA-Approved Treatment; Other: No intervention for Control Group
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified September 2011
A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities

Conditions: Hypertension; Asthma
Interventions: Other: PPCM Asthma; Other: 24 Month PPCM BP; Other: 9 Month PPCM HTN
Sponsors: University of Iowa; University of Iowa
Recruiting - verified June 2010
Eosinophilic Airway Inflammation and Mepolizumab

Condition: Asthma
Intervention: Biological: mepolizumab
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified August 2011
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012